STERIS(STE) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total as-reported revenue grew by 9% in Q3 2026, with constant currency organic revenue growth of 8% driven by volume and a 200 basis points price increase [4] - Gross margin declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation, despite positive pricing and productivity [4] - EBIT margin decreased by 40 basis points to 22.9% of revenue, mainly due to the decline in gross margin [4] - Adjusted net income from continuing operations was $249.4 million, with earnings per diluted share increasing by 9% to $2.53 [5] - Free cash flow for the first nine months of fiscal 2026 was $736.6 million, showing year-over-year improvement [6] Business Line Data and Key Metrics Changes - Healthcare segment saw constant currency organic revenue growth of 8%, with service growth at 11% and consumables at 8% [7] - Healthcare capital equipment revenue increased by 7%, with backlog remaining over $400 million [7] - AST segment reported constant currency organic revenue growth of 8%, with services growing by 9% and capital equipment revenue increasing by 103% [8] - Life sciences segment experienced a 5% increase in constant currency organic revenue, driven by 11% growth in consumables [8] Market Data and Key Metrics Changes - Orders in the healthcare segment were down 1% year-to-date, facing tough comparisons to the previous year [7] - The backlog in life sciences is showing strong growth, attributed to a recovery in the market compared to a year ago [16] Company Strategy and Development Direction - The company is maintaining its fiscal 2026 outlook, expecting 8%-9% as-reported revenue growth and constant currency organic revenue growth of 7%-8% [9] - The company is focused on mitigating tariff impacts through various strategies, including supplier negotiations and cost reductions [24] - There is a commitment to a more integrated commercial approach in the EMEA region, with structural changes being made to enhance market presence [34] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding Q4 growth due to a slowdown in the second half and tough comparisons to last year's strong performance [12][14] - The macro environment appears positive, with no significant downside anticipated for fiscal 2027 [50] Other Important Information - The adjusted effective tax rate for the quarter was 24.2%, a slight decline from the previous year [5] - Capital expenditures for the first nine months totaled $278.8 million, with depreciation and amortization at $363.1 million [6] Q&A Session Summary Question: Insights on Q4 constant currency growth - Management noted a slowdown in the second half and maintained a cautious outlook for Q4, particularly due to tough comparisons from the previous year [12][13] Question: Capital equipment backlog activity - Management indicated stability in healthcare backlog and strong growth in life sciences backlog, attributed to improved market conditions [16] Question: Update on tariff mitigation efforts - Management discussed various mitigation strategies, including shifting product movement and seeking cost reductions [24] Question: Impact of regulatory proposals on supply chain - Management stated that the ASC shift is generally positive, creating new capacity demands, but noted no significant impact from recent regulatory proposals yet [31] Question: Future acquisition plans - Management confirmed ongoing interest in smaller acquisitions but emphasized a disciplined approach to larger transformative deals [44] Question: Cash flow guidance and fluctuations - Management expressed confidence in cash flow guidance but noted potential timing issues in Q4 that could affect collections [48] Question: AST Services growth and market conditions - Management acknowledged a weak start to the quarter but noted improvement by December, attributing some fluctuations to customer inventory adjustments [57][58]